Related references
Note: Only part of the references are listed.VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2022)
IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
C. Zhou et al.
ANNALS OF ONCOLOGY (2021)
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
Bin Qiu et al.
NATURE COMMUNICATIONS (2021)
FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
B.C. Cho et al.
Journal of Thoracic Oncology (2021)
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
Joseph C. Del Paggio et al.
JAMA ONCOLOGY (2021)
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.
Hirohito Tada et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer.
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Mathieu Chevallier et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2021)
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Jhanelle E. Gray et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Learning from clinical trials of neoadjuvant checkpoint blockade
Judith M. Versluis et al.
NATURE MEDICINE (2020)
KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
J. R. Brahmer et al.
ANNALS OF ONCOLOGY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
Muyun Peng et al.
FRONTIERS IN ONCOLOGY (2020)
Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer
David B. Nelson et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong et al.
LANCET ONCOLOGY (2018)
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study
Christos Chouaid et al.
LUNG CANCER (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Heather A. Wakelee et al.
LANCET ONCOLOGY (2017)
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel A. Chaudhuri et al.
CANCER DISCOVERY (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. E. Postmus et al.
ANNALS OF ONCOLOGY (2017)
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
B. Besse et al.
ANNALS OF ONCOLOGY (2017)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting
Dario Consonni et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
Ahmad A. Tarhini et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting
Dario Consonni et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer
Matthew D. Taylor et al.
ANNALS OF THORACIC SURGERY (2012)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Recurrence Dynamics for Non-Small-Cell Lung Cancer Effect of Surgery on the Development of Metastases
Romano Demicheli et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer
Zachary D. Horne et al.
JOURNAL OF SURGICAL RESEARCH (2011)
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer
Guanchao Jiang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2011)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection
Hiroshi Sugimura et al.
ANNALS OF THORACIC SURGERY (2007)
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer
J Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
